Company Overview

EyePoint, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing sustained-release drug delivery technologies for ophthalmic diseases. The company operates within the ophthalmology and specialty pharmaceuticals industries, with a strategic emphasis on retinal and posterior segment eye diseases that require long-term treatment. EyePoint’s core competency lies in combining proprietary drug delivery platforms with well-characterized therapeutic agents to improve dosing durability, patient compliance, and clinical outcomes.

The company’s primary value drivers include its proprietary Durasert® sustained-release technology and a pipeline of product candidates targeting chronic retinal conditions such as wet age-related macular degeneration (wet AMD) and diabetic eye diseases. EyePoint evolved from pSivida Corp., which historically focused on ocular drug delivery implants, and completed a corporate rebranding to EyePoint, Inc. to reflect its sharpened focus on ophthalmology and later-stage product development. Its strategy positions the company as a differentiated developer of long-acting ocular therapeutics in markets dominated by frequent intravitreal injections.

Business Operations

EyePoint generates and seeks to generate value through the development, regulatory approval, and commercialization of ophthalmic therapeutics using its proprietary delivery platforms. Its operations are primarily organized around research and development, clinical advancement, and lifecycle management of product candidates rather than diversified commercial segments. The company previously commercialized products such as YUTIQ® and DEXYCU®, both based on Durasert® technology, though current revenue is limited and primarily associated with legacy product sales, licensing arrangements, and collaboration-related income. Data on the long-term commercial contribution of these products is limited based on available public disclosures.

Operationally, EyePoint conducts the majority of its research, clinical development, and corporate management activities in the United States, while utilizing third-party manufacturers and clinical research organizations. The company retains ownership of its core drug delivery intellectual property and does not rely on large-scale manufacturing assets. EyePoint has historically engaged in selective partnerships to support development and commercialization, though no transformative joint ventures are consistently identified across public sources. Where revenue mix or segment reporting varies across disclosures, data is inconclusive based on available public sources.

Strategic Position & Investments

EyePoint’s strategic direction centers on advancing long-acting injectable therapies that can meaningfully reduce treatment burden in chronic retinal diseases. A key growth initiative is the development of DURAVYU™, a sustained-release intravitreal formulation of vorolanib designed for wet AMD, which represents the company’s most significant clinical-stage asset. Investment priorities are heavily weighted toward clinical trials, regulatory engagement, and pipeline expansion using the Durasert® platform rather than broad-based acquisitions.

The company has historically rationalized its portfolio by divesting non-core assets and narrowing its focus to fewer, higher-impact ophthalmic programs. EyePoint does not currently disclose a broad portfolio of operating subsidiaries or minority equity investments, and its strategy emphasizes internal development over external acquisition. Emerging technologies of interest include bioerodible implants and extended-duration ocular therapeutics, though commercialization timelines remain subject to clinical and regulatory outcomes.

Geographic Footprint

EyePoint is headquartered in the United States, with its principal executive offices located in Massachusetts. Its operational footprint is primarily domestic, reflecting its focus on U.S.-based research, clinical development, and regulatory activities. The company’s clinical trials and regulatory strategy, however, are designed to support potential commercialization in North America, Europe, and other major ophthalmic markets.

International exposure is largely indirect, achieved through global clinical trial sites and the potential for future licensing or commercialization arrangements outside the United States. EyePoint does not currently report significant standalone international operations or manufacturing facilities, and its global influence is primarily tied to the prospective reach of its product candidates rather than existing overseas infrastructure.

Leadership & Governance

EyePoint is led by an executive team with deep experience in ophthalmology, drug development, and regulated healthcare markets. The leadership emphasizes disciplined capital allocation, clinical rigor, and a strategic focus on long-acting therapies that address unmet needs in retinal disease. Governance practices align with those of a publicly traded biotechnology company, with oversight from an independent board of directors and adherence to U.S. securities reporting standards.

Key executives include:

• Jay S. Duker, M.D. – President and Chief Executive Officer
• Christopher Prentice – Chief Financial Officer and Chief Business Officer
• Nancy Lurker – Chair of the Board of Directors
• Michael Colucci – Chief Development Officer
• Andrew T. Crockett – Chief Legal Officer and Corporate Secretary

Leadership backgrounds and roles are consistently reported across public company filings and investor disclosures, though minor title variations may exist across reporting periods.